Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Last Close
Apr 18 03:54PM ET
1.31
Dollar change
-0.13
Percentage change
-9.03
%
Index- P/E- EPS (ttm)-0.27 Insider Own2.20% Shs Outstand256.57M Perf Week-22.49%
Market Cap336.01M Forward P/E- EPS next Y-0.26 Insider Trans0.00% Shs Float250.87M Perf Month19.09%
Income-64.56M PEG- EPS next Q-0.07 Inst Own10.23% Short Float17.33% Perf Quarter153.58%
Sales1.41M P/S238.31 EPS this Y1.75% Inst Trans-2.91% Short Ratio4.96 Perf Half Y207.51%
Book/sh0.16 P/B8.29 EPS next Y7.14% ROA-74.16% Short Interest43.48M Perf Year49.73%
Cash/sh0.15 P/C8.52 EPS next 5Y- ROE-103.61% 52W Range0.34 - 2.11 Perf YTD127.83%
Dividend Est.- P/FCF- EPS past 5Y41.20% ROI-137.55% 52W High-37.77% Beta3.48
Dividend TTM- Quick Ratio2.51 Sales past 5Y- Gross Margin31.23% 52W Low279.71% ATR (14)0.20
Dividend Ex-Date- Current Ratio2.51 EPS Y/Y TTM7.95% Oper. Margin0.00% RSI (14)44.51 Volatility11.13% 14.54%
Employees65 Debt/Eq0.17 Sales Y/Y TTM- Profit Margin-4581.62% Recom1.00 Target Price7.50
Option/ShortYes / Yes LT Debt/Eq0.16 EPS Q/Q57.07% Payout- Rel Volume0.85 Prev Close1.44
Sales Surprise- EPS Surprise-8.33% Sales Q/Q- EarningsApr 02 BMO Avg Volume8.77M Price1.31
SMA20-19.07% SMA5011.93% SMA200103.65% Trades Volume7,377,931 Change-9.03%
Date Action Analyst Rating Change Price Target Change
Mar-01-23Upgrade Chardan Capital Markets Neutral → Buy $3.50
Aug-23-22Initiated Mizuho Buy $5
Jun-15-22Resumed ROTH Capital Buy $8
Jun-02-22Initiated Cantor Fitzgerald Overweight $4.50
Jul-26-21Initiated Noble Capital Markets Outperform
Jun-11-21Downgrade ROTH Capital Buy → Neutral $10 → $6
May-07-21Downgrade Cantor Fitzgerald Overweight → Neutral
Feb-09-21Downgrade Chardan Capital Markets Buy → Neutral $0.70 → $13
Feb-04-21Upgrade H.C. Wainwright Neutral → Buy $4.50
Apr-16-24 10:53PM
Apr-12-24 07:30AM
Apr-10-24 07:02AM
Apr-08-24 12:13PM
10:57AM
06:30AM Loading…
06:30AM
Apr-05-24 03:30PM
07:02AM
Apr-02-24 10:50PM
07:00PM
03:15PM
08:00AM
Apr-01-24 06:08PM
05:43PM
Mar-25-24 11:58AM
07:32AM Loading…
07:32AM
Mar-18-24 06:30AM
Mar-13-24 08:00AM
Mar-07-24 05:28AM
Mar-06-24 07:30AM
Feb-28-24 08:00AM
Feb-26-24 04:34PM
08:30AM
Feb-22-24 04:05PM
12:56PM
Feb-21-24 04:05PM
Feb-20-24 10:26AM
Feb-14-24 07:30AM
Jan-31-24 08:00AM
Jan-16-24 07:30AM
06:30AM Loading…
Dec-21-23 06:30AM
Dec-19-23 07:30AM
Dec-13-23 07:30AM
Nov-29-23 07:30AM
Nov-10-23 01:54PM
07:30AM
02:07AM
Nov-09-23 11:45AM
08:38AM
07:00AM
06:30AM
Nov-07-23 07:45AM
Nov-02-23 07:30AM
Oct-10-23 09:58AM
06:30AM
Oct-04-23 07:00AM
Sep-29-23 07:30AM
Sep-27-23 07:30PM
Sep-21-23 07:30AM
Sep-20-23 08:00AM
Sep-13-23 08:15AM
Sep-12-23 07:30PM
Aug-24-23 09:48AM
Aug-23-23 02:05AM
Aug-22-23 12:00PM
Aug-21-23 04:32PM
Aug-18-23 04:39PM
Jul-25-23 08:58PM
Jul-13-23 07:00AM
Jun-30-23 08:00AM
Jun-09-23 04:05PM
Jun-05-23 07:02AM
May-25-23 02:00PM
May-24-23 08:36AM
May-23-23 04:01PM
08:00AM
May-05-23 03:00PM
07:17AM
07:00AM
Apr-28-23 07:00AM
Apr-27-23 07:25AM
Apr-26-23 06:30AM
Apr-20-23 08:00AM
Apr-14-23 01:47PM
07:45AM
Apr-11-23 06:20PM
Mar-31-23 08:15AM
Mar-27-23 08:00AM
Mar-07-23 08:00AM
Mar-06-23 07:02AM
Mar-02-23 07:02AM
Mar-01-23 06:16AM
02:17AM
Feb-28-23 06:04PM
04:00PM
07:00AM
Feb-27-23 05:57PM
Feb-17-23 08:00AM
Feb-16-23 05:30AM
Feb-15-23 04:30PM
Feb-04-23 05:30AM
Feb-03-23 11:18AM
Feb-01-23 01:55PM
08:00AM
Jan-31-23 08:00AM
Jan-29-23 07:00AM
Jan-26-23 05:21AM
Jan-23-23 05:21AM
Jan-11-23 07:03AM
Jan-09-23 08:33AM
Ocugen, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapies to cure eye diseases. Its product pipeline candidates include OCU400, OCU410, OCU200, and COVAXIN. The firm's modifier gene therapy platform is engaged in addressing retinal diseases, including retinitis pigmentosa, leber congenital amaurosis, and dry age-related macular degeneration. The company was founded by Shankar Musunuri and Uday B. Kompella in 2013 and is headquartered in Malvern, PA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Zhang JungeDirectorJun 14 '23Buy0.50200,27899,9991,077,182Jun 16 04:22 PM